Aleva Neurotherapeutics
PrivateLast Round
Convertible Debt
Dec 23, 2021
Total Funding Raised
$62.5M
Momentum
Top 50%
of companies Caplight tracks
Company Overview
Aleva Neurotherapeutics operates in Healthcare & Life Sciences and is based in Lausanne. Its latest recorded funding round was a Convertible Debt round in December 2021.
Aleva Neurotherapeutics is a medical device company that develops, manufactures, and commercializes implantable deep brain stimulation (DBS) systems for the treatment of neurological diseases such as Parkinson's and essential tremor.
Sector
Healthcare & Life Sciences
Verticals
Medical Devices, Biotech Equipment
Business Model
B2B
Customer Profile
Hardware Sales
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Aleva Neurotherapeutics Comparables
Compare Aleva Neurotherapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Newronika | 87% | |
| Beijing PINS Medical Co., Ltd. | 85% | |
| 景昱医疗科技（苏州）股份有限公司 | 83% |
For institutional investors. Book with your work email.
Aleva Neurotherapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Convertible Debt | Dec 23, 2021 | ||||
| Series E | Dec 16, 2019 | ||||
| Series D | Oct 3, 2017 | ||||
| Series C | May 27, 2016 | ||||
| Series B | Apr 10, 2012 | ||||
Series A | Aug 26, 2011 |
For institutional investors. Book with your work email.
Aleva Neurotherapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| BioMedPartners | Series B, Series C, Series E, Series D, Series A |
| Kreaxi | Series C, Series E, Series D, Series B |
| BB Biotech Ventures | Series C, Series E, Series D |
| Kinled Holding | Series C, Series E, Series D |
| River Merchant Capital | Convertible Debt |
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 21, 2026
Monthly visitors grew 190% MoM, from 386 to 1.1K.
- Dec 23, 2021
$5.4M raised from River Merchant Capital.
For institutional investors. Book with your work email.
Aleva Neurotherapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Aleva Neurotherapeutics's valuation, stock price, and market status.
Is Aleva Neurotherapeutics a public or private company?
Aleva Neurotherapeutics is a private company.
What is the current stock price of Aleva Neurotherapeutics?
Aleva Neurotherapeutics is a private company, so its shares have no public market price. Caplight tracks Aleva Neurotherapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Aleva Neurotherapeutics worth (valuation)?
Valuation information for Aleva Neurotherapeutics is not publicly available.
Can I buy Aleva Neurotherapeutics stock?
Aleva Neurotherapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Aleva Neurotherapeutics's last funding round?
Aleva Neurotherapeutics's most recent funding round was Convertible Debt on December 23, 2021.
Who are the main investors in Aleva Neurotherapeutics?
Key investors in Aleva Neurotherapeutics include BioMedPartners, Kreaxi.
Will Aleva Neurotherapeutics IPO soon?
No public IPO plans have been announced for Aleva Neurotherapeutics.
How can I track Aleva Neurotherapeutics secondary market activity?
Caplight tracks bids, offers, and trades in Aleva Neurotherapeutics's shares on secondary markets.